BONE DENSITY IN SURVIVORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

小儿急性淋巴细胞白血病幸存者的骨密度

• 批准号: 6264297
• 负责人: NINA S KADAN-LOTTICK
• 金额: $ 1.99万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264297
• 关键词: acute lymphocytic leukemia; blood disorder chemotherapy; bone density; bone metabolism disorder; child (0-11); clinical research; comorbidity; disease /disorder proneness /risk; human subject; human therapy evaluation; long term survivor; neoplasm /cancer chemotherapy; neoplasm /cancer epidemiology; osteopenia; osteoporosis; pediatric neoplasm /cancer

Disruption of bone metabolism in children with acute lymphoblastic leukemia (ALL) by both leukemic processes and chemotherapeutic drugs potentially decreases peak bone mass, predisposing these individuals to osteoporosis and osteopenia. This cross-sectional study will determine the prevalence of osteopenia and osteoporosis in survivors of ALL and identify associated risk factors.

白血病过程和化疗药物对急性淋巴细胞白血病（ALL）儿童骨代谢的破坏可能会降低峰值骨量，使这些个体易患骨质疏松症和骨量减少。 这项横断面研究将确定ALL幸存者中骨量减少和骨质疏松症的患病率，并确定相关的风险因素。